Akebia Therapeutics announced the establishment of a rare kidney disease pipeline.
The pipeline includes ADX-097, a complement inhibitor, and praliciguat, an sGC stimulator.
Akebia acquired ADX-097 from Q32 Bio and initiated a Phase 2 trial for praliciguat in FSGS.
Pipeline Introduction
Akebia's rare kidney disease pipeline comprises ADX-097 and praliciguat to address complement-mediated rare kidney diseases.
Complement Inhibition Mechanism
ADX-097 functions by specifically binding to complement proteins, halting inflammatory responses and cell destruction.
Financial Agreement
Akebia acquired ADX-097 from Q32 Bio in an Asset Purchase Agreement for $7.0 million upfront and potential additional payments.
- Akebia's pipeline aims to provide innovative treatments for rare kidney diseases.
- The acquisition of ADX-097 and initiation of praliciguat trials mark significant progress in Akebia's development strategy.
Akebia's focus on rare kidney diseases through ADX-097 and praliciguat showcases its commitment to advancing kidney disease treatments. The company's strategic acquisitions and trial initiations signal promising developments for the future of kidney disease therapies.